** Shares of medtech firm Lensar LNSR.O fall 3.7% to $14.27
** LNSR has agreed to be acquired by Swiss eyecare firm Alcon ALCC.S for $14/shr, totaling around $356 million
** Deal represents a 5.6% discount to LNSR's last close
** U.S.-listed shares of Alcon ALC.N up 1.8% at $92.18
** Alcon may pay Lensar an additional $2.75/shr, totaling up to $430 million, if certain procedure targets are met
** Deal is expected to close in mid-to-late 2025
** LNSR up more than four-fold and U.S.-listed shares of ALC up 7.9% in the last 12 months
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.